Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ: AZN )

73.58 -0.87 (-1.17%)
Official Closing Price Updated: 4:15 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
From AstraZeneca
Via Business Wire
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines globally by 2030. 
Via Benzinga
Robbins LLP Encourages AZN Shareholders with Large Losses to Seek Counsel in the AstraZeneca PLC Class Action
From Robbins LLP
Via GlobeNewswire
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NASDAQ:GILD),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus
From FN Media Group LLC
Via GlobeNewswire
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data. 
Via Benzinga
Exposures Product Safety
Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Quantum computing is in its early stages, but investors may benefit from the incremental progress being made by these three companies 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN
From The Rosen Law Firm PA
Via GlobeNewswire
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
From AstraZeneca
Via Business Wire
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives and focusing on innovative cancer drugs. 
Via Benzinga
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma
AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression. 
Via Benzinga
Exposures Product Safety
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 – AZN
From Faruqi & Faruqi LLP
Via GlobeNewswire
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
From AstraZeneca
Via Business Wire
3 High-Yielding Dividend Stocks That Are Trading at Dirt Cheap Prices
Via The Motley Fool
AZN DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 21, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AZN DEADLINE: Investors Are Encouraged to Contact Kaplan Fox Before the Lead Plaintiff Deadline on February 21, 2025
NEW YORK - January 14, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on... 
Via TheNewswire.com
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action
From Robbins LLP
Via GlobeNewswire
AZN Deadline to Lead in Securities Fraud Lawsuit is February 21, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
AZN Deadline to Lead in Securities Fraud Lawsuit is February 21, 2025 - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - January 13, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on... 
Via TheNewswire.com
Topics Fraud Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
< Previous 1 2 3 4 5 6 7 8 9
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.